



**VERTEX PHARMACEUTICALS INCORPORATED**  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel. 617.444.6100 Fax 617.444.6680  
www.vrtx.com

**FAX**

**RECEIVED**  
**CENTRAL FAX CENTER**

<b>To</b>	Examiner Taofiq A. Solola
<b>Company</b>	USPTO
<b>FAX</b>	(703) 872-9306
<b>From</b>	Karen E. Brown
<b>Date</b>	March 4, 2005
<b>Subject</b>	Application No. 10/686,690 Attorney Docket No. VPI/00-127 CON DIV US
<b>Total Pages</b>	11

**Message or Comment**

In response to the Notice of Non-Compliant Amendment in the above-identified application.

***CERTIFICATE OF FACSIMILE TRANSMISSION***

I hereby certify that this correspondence, and any documents referred to as attached hereto, is/are being transmitted to the United States Patent and Trademark Office, Facsimile Number: (703) 872-9306 on this 4th day of March 2005.

*Susan Betty-Dinn*  
Signature

If any problems occur with this fax transmittal, please call (617) 444-6467 immediately.

**FAX Number (617) 444-6483 Legal Department**

**CONFIDENTIALITY NOTICE**

The information and the documents transmitted by this telecopy are privileged and contain confidential information intended only for the person(s) names above. Any other distribution, copying or disclosure is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original to us without making a copy.

RECEIVED  
CENTRAL FAX CENTER

MAR 04 2005

For Other Than A Small Entity

VPI/00-127 CON DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/686,690  
Confirmation No.: 7672  
Filing Date: October 16, 2003  
Examiner: Taofiq A. Solola  
Group Art Unit: 1626  
Applicant: Michael Hale et al.  
For: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK

Cambridge, Massachusetts  
March 4, 2005

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: ☒ a Response to Notice of Non-Compliant Amendment; ☐ a Petition for Extension of Time; ☐ a substitute Specification; ☐ a Declaration; ☐ a Supplemental Declaration; ☐ a Power of Attorney; ☐ an Associate Power of Attorney; ☐ formal drawings; to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS


- ☒ A fee for additional claims is not required.
- ☐ A fee for additional claims is required.
- ☐ A check in the amount of \$\_\_\_ in payment of the filing fee is transmitted herewith.

Application No.: 10/686,690  
Applicants: Michael Hale et al.  
Page 2

- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☐ Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE

- ☐ The following extension is applicable to the Response filed herewith; ☐ \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- ☐ A check in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 in payment of the extension fee is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☐ Please charge the ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00; extension fee to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

  
Karen E. Brown  
Registration No. 43,866  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617) 444-6168  
Fax.: (617) 444-6483

RECEIVED  
CENTRAL FAX CENTER

MAR 04 2005

For Other Than A Small Entity

VPI/00-127 CON DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/686,690  
Confirmation No.: 7672  
Filing Date: October 16, 2003  
Examiner: Taofiq A. Solola  
Group Art Unit: 1626  
Applicant: Michael Hale et al.  
For: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK

Cambridge, Massachusetts  
March 4, 2005

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: ☒ a Response to Notice of Non-Compliant Amendment; ☐ a Petition for Extension of Time; ☐ a substitute Specification; ☐ a Declaration; ☐ a Supplemental Declaration; ☐ a Power of Attorney; ☐ an Associate Power of Attorney; ☐ formal drawings; to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS


- ☒ A fee for additional claims is not required.
- ☐ A fee for additional claims is required.
- ☐ A check in the amount of \$\_\_\_ in payment of the filing fee is transmitted herewith.

Application No.: 10/686,690  
Applicants: Michael Hale et al.  
Page 2

- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☐ Please charge \$\_\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE

- ☐ The following extension is applicable to the Response filed herewith; ☐ \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- ☐ A check in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 in payment of the extension fee is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☐ Please charge the ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00; extension fee to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.



Karen E. Brown  
Registration No. 43,866  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617) 444-6168  
Fax.: (617) 444-6483

RECEIVED  
CENTRAL FAX CENTER

MAR 04 2005

VPI/00-127 CON DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/686,690  
Confirmation No.: 7672  
Filing Date: October 16, 2003  
Examiner: Taofiq A. Solola  
Group Art Unit: 1626  
Applicant: Michael Hale et al.  
For: PYRAZOLE COMPOSITIONS USEFUL AS  
INHIBITORS OF ERK

Cambridge, Massachusetts  
March 4, 2005

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

Sirs:

This is in response to the February 18, 2005 Notice of Non-Compliant  
Amendment in the above-identified application. A response is due March 18, 2005.  
Thus, this response is timely filed.

Amendments to the claims begin on page 2.

Remarks begin on page 8.